Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 11/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20588071 | 0.85 | HCAR3 (0.76) | HCAR3HPGDHCAR2NAMPTPOLB | |
| SCHEMBL23558529 | 0.85 | HCAR3 (0.67) | HCAR3HPGDHCAR2NAMPTPOLB | |
| SCHEMBL10242669 | 0.80 | HCAR3 (0.78) | HCAR3HPGDHCAR2POLBMAPT | |
| SCHEMBL1020492 | 0.79 | HCAR3 (0.76) | HCAR3HPGDHCAR2NAMPTPOLB | |
| SCHEMBL29673286 | 0.78 | HCAR3 (0.70) | HCAR3HPGDHCAR2POLBMAPT | |
| SCHEMBL20587465 | 0.78 | HCAR3 (0.70) | HCAR3HPGDHCAR2POLBMAPT | |
| SCHEMBL20587471 | 0.77 | HCAR3 (0.72) | HCAR3HPGDHCAR2POLBMAPT | |
| SCHEMBL31304538 | 0.76 | HCAR3 (0.58) | HCAR3HPGDHCAR2HTTPOLB | |
| SCHEMBL13322638 | 0.76 | HCAR3 (0.58) | HCAR3HPGDHCAR2HTTPOLB | |
| SCHEMBL9525250 | 0.74 | HCAR3 (0.68) | HCAR3HPGDHCAR2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114585360-B | Methods of using the same for treating epilepsy | 特维娜有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-4025211-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | Trevena, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-114585360-A | Methods of using the same for the treatment of epilepsy | 特维娜有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021046183-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046183-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-3638235-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | Trevena, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| CN-110831593-A | Compounds for modulating S1P1 activity and methods of use thereof | 特维娜有限公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2018231745-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | HCAR3 291/4885HPGD 3374/4885HCAR2 286/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | HCAR3 203/4885HPGD 2590/4885HCAR2 80/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | HCAR3 291/4885HPGD 3374/4885HCAR2 286/4885 |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | HCAR3 291/4885HPGD 3374/4885HCAR2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.